Objective To evaluate the clinical efficacy of Chinese medicine compound Actinidia arguta（ 藤梨根） preparation adjuvant chemotherapy in the treatment of advanced colon cancer with spleen deficiency

and to analyze the related factors affecting the progression-free survival of patients. Methods A retrospective analysis of 62 patients with advanced colon cancer admitted to the Department of Oncology

Ningbo City Hospital of Traditional Chinese Medicine from June 2013 to June 2016 was conducted. All patients received a daily dose of compound Actinidia arguta preparation and combined with XELOX or FOLFIRI regimen chemotherapy

with 42 days as a course of treatment

until the disease progresses. Traditional Chinese medicine（ TCM） syndrome scores were evaluated before treatment and after 1 course of treatment

including food intake

body fatigue

abdominal distension

and stool abnormalities; the progression-free survival of patients was observed and its influencing factors were analyzed; The shortterm clinical efficacy

TCM syndrome efficacy and quality of life efficacy after 1 course of treatment were evaluated.Results The scores of TCM syndromes were significantly lower after treatment for 1 course of treatment（ P < 0. 05）.After 1 course of treatment

the patient ’s short-term clinical efficacy was 58. 1%

and the clinical benefit rate was82. 3%. TCM syndrome efficacy: 34 cases were markedly effective

15 cases were effective

13 cases were ineffective. Efficacy on quality of life: 10 cases were significantly improved

25 cases were improved

14 cases were stable and 13 cases were decreased. The median progression-free survival was 28 weeks. Univariate analysis showed that progression-free survival was associated with previous radical surgery

number of cancer metastases

visceral metastasis

and metastatic organ（ P < 0. 05）. Multivariate analysis showed that the progression risk was increased by 5. 733 times for each increase of number of cancer metastasis

and the risk of visceral metastasis was 10. 100 times higher than that of no visceral metastasis. The risk was increased by 1. 680 times for each progression of metastatic organs.Conclusion The effective rate of compound Actinidia arguta preparation adjuvant chemotherapy in the treatment of advanced colon cancer patients with spleen deficiency is as high as 58. 1%

and the patients with smaller number of cancer metastases

no visceral metastasis and fewer metastatic organs have longer progression-free survival period.